Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model

Xingchen Bian, Xiaofen Liu, Yuancheng Chen, Daijie Chen, Jian Li, Jing Zhang
Xingchen Bian
aInstitute of Antibiotics, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
bCollege of Life Sciences, Shanghai Normal University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaofen Liu
aInstitute of Antibiotics, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuancheng Chen
aInstitute of Antibiotics, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
cPhase I Unit, Huashan Hospital, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daijie Chen
dShanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Li
eBiomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Zhang
aInstitute of Antibiotics, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
cPhase I Unit, Huashan Hospital, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01989-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Static time-kill curves show the bactericidal effect of colistin (blue), meropenem (orange), and their combination (green) against carbapenem-resistant A. baumannii isolates (mean ± SD, n = 3). CST, colistin; MEM, meropenem.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Dynamic in vitro PK/PD killing kinetics of ATCC 19606 (A), AB1845 (B), and AB2092 (C) in different dosage regimens. Meropenem dose of 0.5 g is infused for 0.5 h, and 1 or 2 g is for 3-h infusion. CST, colistin; MEM, meropenem.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    The values of ΔlogCFU0–24 for ATCC 19606, AB1845, and AB2092 after each monotherapy and the combination.

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    Observed (symbols) and model fitted (lines) viable counts for the dynamic in vitro PK/PD model experiments with colistin or meropenem alone and the combination against A. baumannii ATCC 19606 (A), AB1845 (B), and AB2092 (C). Meropenem dose of 0.5 g is infused for 0.5 h, and 1 or 2 g is for 3-h infusion. CST, colistin; MEM, meropenem.

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    Diagnostic plots of fitting results for ATCC 19606, AB1845, and AB2092 and validation results for AB2092. Meropenem was dosed at 2 g every 8 h with 8-h infusion.

  • FIG 6
    • Open in new tab
    • Download powerpoint
    FIG 6

    Validation of the PK/PD modeling for the regimen of 1 mg/liter colistin in combination with 2 g meropenem every 8 h with 8-h infusion.

  • FIG 7
    • Open in new tab
    • Download powerpoint
    FIG 7

    Pharmacodynamic predictions of colistin and meropenem mono- and combination therapy against A. baumannii AB1845(A) and AB2092(B). The units for colistin and meropenem are mg/liter at steady state and g with 3-h infusion, respectively. LOD, 1 log10 CFU/ml.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Δ logCFU0–24 values of colistin and meropenem as monotherapy and in combination

    Strain (MICCST/MICMEM)ΔlogCFU0–24 by antibiotic therapy (mean ± SD) (n = 3)
    No drugColistinMeropenemCombination
    050111 (0.5/128)2.62 ± 0.121.13 ± 1.502.69 ± 0.24−5.25 ± 1.93
    AB1845 (0.5/32)1.81 ± 0.082.19 ± 0.171.86 ± 0.09−6.1 ± 0.92
    AB2092 (1/128)2.11 ± 0.101.58 ± 0.302.04 ± 0.14−6.52 ± 0.24
  • TABLE 2

    Values of %T>MIC, %T>2MIC, and %T>3MIC for AB2092 with different dosing regimensa

    Meropenem dosage (g)Infusion value (mg/liter)MIC at an infusion duration (h) of:
    1238
    1%T>MIC (8)2532380
    %T>2MIC (16)16183.60
    %T>3MIC (24)9.4000
    2%T>MIC (8)37445190
    %T>2MIC (16)2632380
    %T>3MIC (24)2025270
    • ↵a MIC values refer to those in the checkerboard assay.

  • TABLE 3

    Parameter estimates for the in vitro PK/PD model

    ParameterExplanationValue for strain:
    ATCC 19606A. baumannii 1845A. baumannii 2092
    kgrowth (h−1)Rate constant of bacterial net growth0.2501.010.640
    Bmax (log10CFU/ml)Bacterial count in the stationary phase8.568.028.03
    Emax_CST (h−1)Maximum achievable kill rate constant by colistin7.210.9984.66
    EC50_CST (mg/liter)Colistin concentration that results in 50% of Emax0.07150.3740.730
    Emax_MEM (h−1)Maximum achievable kill rate constant by meropenem1.110.9470.095
    EC50_MEM (mg/liter)Meropenem concentration that results in 50% of Emax15.514.813.5
    γCSTHill factor for colistin1.271.051.55
    γMEMHill factor for meropenem0.3060.7737.30
    fMaximal adaptation factor2903.609.54
    kRate of adaptation1.060.1560.444
    IntParameter describing drug interaction0.1900.01180.0117
    fval (%)Residual error fraction5.993.772.23

Additional Files

  • Figures
  • Tables
  • Supplemental material

    • Supplemental file 1 -

      Tables S1 to S5 and Fig. S1 to S6

      PDF, 433K

PreviousNext
Back to top
Download PDF
Citation Tools
Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
Xingchen Bian, Xiaofen Liu, Yuancheng Chen, Daijie Chen, Jian Li, Jing Zhang
Antimicrobial Agents and Chemotherapy Mar 2019, 63 (4) e01989-18; DOI: 10.1128/AAC.01989-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
Xingchen Bian, Xiaofen Liu, Yuancheng Chen, Daijie Chen, Jian Li, Jing Zhang
Antimicrobial Agents and Chemotherapy Mar 2019, 63 (4) e01989-18; DOI: 10.1128/AAC.01989-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Acinetobacter baumannii
PK/PD modeling
carbapenem resistance
colistin
combination therapy
meropenem

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596